Cover Image
市場調查報告書

全球抗肥胖症處方藥市場策略性分析

A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market

出版商 Frost & Sullivan 商品編碼 300898
出版日期 內容資訊 英文 64 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗肥胖症處方藥市場策略性分析 A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market
出版日期: 2014年04月18日 內容資訊: 英文 64 Pages
簡介

受到各國政府的新支援政策、加上二種新醫藥品的認証、其他藥劑緊急認証等動態影響,減肥處方藥再度受到世人的注目。

本報告提供全球治療肥胖症用的處方藥市場上競爭狀態相關分析,提供已上市/開發平台上的各種藥物簡介,及醫藥品的各級分類,過去的市場趨勢與今後的預測,臨床實驗的設計·認證相關法規的指南,全球各國的肥胖症的流行病學的情形等調查,並將結果概述為以下內容。

第1章 摘要整理

  • 市場趨勢(2013年第一季以後)
  • 摘要整理
  • 藥物研發合作夥伴
  • 值得注意的企業

第2章 分析範圍·手法

第3章 全球抗肥胖症處方藥市場:簡介

  • 肥胖症的背景情況
  • 抗肥胖症藥的過去·未來:年表
  • 未來性的處方行動方案
  • 抗肥胖症藥臨床實驗的設計:法規當局的建議
  • 醫藥品認證的建議:地區間比較
  • 全球各地區肥胖症的患病情形
  • 市場概況·分類

第4章 競爭環境

  • 抗肥胖症處方藥的市場:競爭環境
  • 現在進行中的第三階段臨床實驗
  • 現在進行中的肥胖症治療藥上市後臨床實驗
  • 肥胖症治療藥的有效性比較分析
  • 近幾年通過認証的抗肥胖症藥關鍵試驗(Pivotal Trial)計劃
  • 臨床實驗最後階段的抗肥胖症藥的關鍵試驗計劃
  • 已上市產品概要
  • 開發平台產品概要
  • 產品開發動態即時看板系統:Qsymia (phentermine/topiramat ER)
  • 產品開發動態即時看板系統:Belviq (lorcaserin HCl)
  • 產品開發動態即時看板系統:Contrave (bupropion SR/ naltrexone SR)
  • 產品開發動態即時看板系統:Victoza (liraglutide)

第5章 結論與建議

  • 結論與建議
  • 法律上的免責聲明

第6章 附錄

  • 決策依據的資料庫:全球各國的肥胖症患病情形
  • 參考文獻一覽

第7章 關於Frost&Sullivan

目錄
Product Code: NDDE-01-00-00-00

Competition in Revived Market Heats Up with Recent and Pending New Drug Approvals

Prescription drug therapy for the treatment of obesity is experiencing a revival of interest with new government incentives and the recent approval of 2 new drugs, with 2 more pending imminent approval. This research service focuses on the competitive landscape of prescription drugs for the treatment of obesity. A global product and pipeline assessment is provided for marketed and investigational products. Segmentation by drug class is provided along with additional supporting information, such as clinical-trial timelines and results, historical and projected launch timelines, regulatory guidelines for clinical trial design and approval, and global epidemiology by region.

Table of Contents

1. Executive Summary

  • Market Developments Since Q1 2013
  • Executive Summary
  • Drug Discovery Partnerships
  • Companies to Watch

2. Methodology and Scope

3. Introduction to the Global Anti-obesity Prescription Drugs Market

  • Obesity Indication Background
  • Historical and Projected Timeline for Anti-obesity Drugs
  • Potential Prescribing Behavior Scenario
  • Regulators' Recommendations for Designing Anti-obesity Drug Clinical Trials
  • Regional Comparison of Drug Approval Requirements
  • Global Prevalence of Obesity by Region
  • Market Overview-Segmentation

4. Competitive Landscape

  • Anti-obesity Prescription Pharmaceuticals Market-Competitive Landscape
  • Ongoing Phase 3 Trials for Obesity Drugs
  • Ongoing Post-marketing Trials for Obesity Drugs
  • Comparative Efficacy of Obesity Drugs
  • Pivotal Trial Programs of Recently Approved Anti-obesity Drugs
  • Pivotal Trial Programs of Late-stage Anti-obesity Drugs
  • Marketed Products Synopsis
  • Pipeline Synopsis
  • Product Dashboard-Qsymia (phentermine/topiramat ER)
  • Product Dashboard-Belviq (lorcaserin HCl)
  • Product Dashboard-Contrave (bupropion SR/ naltrexone SR)
  • Product Dashboard-Victoza (liraglutide)

5. Conclusions and Recommendations

  • Conclusions and Recommendations
  • Legal Disclaimer

6. Appendix

  • Decision Support Database-Global Prevalence of Obesity
  • List of References

7. The Frost & Sullivan Story

Back to Top